Spinogenix's Tazbentetol Shows Neuroprotective Potential in Diabetic Retinal Neuropathy Study
Event summary
- Spinogenix published peer-reviewed preclinical study results in Experimental Eye Research on October 6, 2026.
- Tazbentetol preserved retinal ganglion cell function and survival in diabetic db/db mice over an 8-week period.
- The treatment restored synaptic proteins, reduced cell death markers, and improved optic nerve myelination without altering blood glucose levels.
- Diabetic retinal neuropathy currently lacks approved therapies targeting neurodegenerative processes.
- Tazbentetol is also in Phase 2 trials for Alzheimer's, ALS, and schizophrenia.
The big picture
Spinogenix's findings position tazbentetol as a potential first-in-class therapy targeting synapse regeneration in diabetic retinal neuropathy, an area with no approved treatments. The results build on previous work in glaucoma models, suggesting broader applicability across neurodegenerative retinal diseases. With existing Phase 2 trials in Alzheimer's, ALS, and schizophrenia, Spinogenix is pursuing a multi-indication strategy that could significantly expand its market potential if clinical success is achieved.
What we're watching
- Clinical Translation
- Whether preclinical results will translate to human trials for diabetic retinal neuropathy.
- Competitive Positioning
- How Spinogenix differentiates tazbentetol in the crowded neurodegenerative disease space.
- Regulatory Pathway
- The pace at which Spinogenix advances tazbentetol through clinical stages for multiple indications.